Special Issue

ESKAPEE: Mechanisms, Spread, and Evolution of Antimicrobial Resistance

Message from the Guest Editors

ESKAPE consists of six bacterial pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. These highly virulent and antibiotic-resistant ESKAPE pathogens are the leading cause of nosocomial infection around the globe. Infections caused by ESKAPE pathogens are frequently associated with limited treatment options, higher risks of therapeutic failure, and increased morbidity and mortality. The growing burden of these infections imposes significant challenges on healthcare systems, necessitating urgent efforts to develop more effective strategies for prevention, diagnosis, and treatment. This Special Issue aims to provide an in-depth discussion of the mechanisms of resistance among ESKAPE pathogens and the spread and evolution of such pathogens, integrating insights from molecular microbiology, evolutionary biology, and epidemiology. Through rigorous scientific analysis, this collection of articles hopes to enhance the understanding of the epidemiological dynamics of ESKAPE pathogens and to inform effective clinical practices and public health policies.

Guest Editors

Dr. Ning Dong
School of Medicine, Zhejiang University, Hangzhou, China

Dr. Yarong Wu
State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China

Deadline for manuscript submissions

closed (31 May 2026)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/236765

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI